Kota Maternity Tragedy: How Fake Oxytocin Triggered a Nationwide Drug Recall

When the first of five women walked into the Government Medical College in Kota in early May, none of them imagined that their births would end in tragedy. Their names – Payal Malaviya, Priya Mahawar, Shirin Kumar, Jyoti Verma and a fifth mother whose story remains largely untold – soon entered the headlines, not for joyful deliveries, but for a silent killer that slipped past the very system meant to protect them.

Oxytocin, a synthetic version of a hormone the body already produces, has been a lifeline for obstetricians worldwide. Administered after Caesarean sections or induced labour, it makes the uterus contract and staunchs the deadly postpartum haemorrhage that claims thousands of lives each year. In the hands of a competent clinician it’s almost a miracle drug – simple, cheap, and usually effective.

What happened in Kota was the opposite of a miracle. According to the State Drug Controller’s report, the batch labelled “Tocin” that arrived at both the Government Medical College and the J. K. Lone Hospital contained nothing but sterile water. No active pharmaceutical ingredient, no lifesaving punch – just a harmless fluid that, in a critical moment, did exactly nothing.

Payal Malaviya, 26, a daily‑wage labourer’s wife, was admitted on 3 May for a scheduled C‑section. The operation went smoothly, the baby – a boy named Nitwik – cried, and for a brief, hopeful instant the family thought the worst was behind them. Then the bleeding wouldn’t stop. Payal’s blood pressure plummeted, she felt a scorching heat, and within hours she slipped into unconsciousness and died, despite frantic transfusions and intensive‑care attempts.

Priya Mahawar, 22, a budding private tutor, faced the same fate days later. After a routine Caesarean, she too went into a rapid, uncontrolled haemorrhage. Her husband, Rohit, recounted how the doctors rescued a newborn but could not save his wife. The pattern was unmistakable – a sudden, severe bleed that no standard protocol seemed to halt.

Behind each heartbreaking story were subtle, shared clues: a sudden drop in blood pressure, an inexplicable sense of overheating, and a desperate reliance on an injection that, in reality, was just water. When the families began to connect the dots, they discovered that the drug administered was the very same “Tocin” batch supplied to the two government hospitals.

The fallout was swift, albeit chaotic. Rajasthan’s health department ordered an immediate halt on all batches of oxytocin from Jackson Laboratories, the manufacturer behind the counterfeit product. The Central Drugs Standard Control Organisation (CDSCO) launched a nation‑wide recall, while the World Health Organization opened a preliminary review of India’s public‑sector drug procurement practices.

Beyond the official paperwork, the human cost is raw. Payal’s infant son now survives on formula, his cries echoing a mother’s absence. Priya’s two‑year‑old daughter is being raised by grandparents, haunted by a picture of a mother who never got to see her grow. Jyoti Verma’s family, once hopeful of a future built beyond caste barriers, now grapples with grief and a gnawing sense of injustice.

Investigators have traced the counterfeit batch to a regional distributor who allegedly sourced the product from an unlicensed supplier in Uttar Pradesh. The distributor, who previously handled legitimate batches for the state, now faces charges of negligence, fraud and criminal breach of trust. Prosecutors say the water‑filled vials were mislabeled with a forged batch number and expiry date, allowing them to slip past routine quality checks.

For the medical community, the episode is a sobering reminder that even the most routine medicines can become weapons in the wrong hands. “We trusted the supply chain,” said Dr. Anil Singh, an obstetrician at JK Lone Hospital. “We never imagined that a syringe could be empty. It forces us to rethink every step – from procurement to the bedside.”

State officials have pledged tighter audits, real‑time testing of active ingredients, and a digital tracking system for all essential medicines entering public hospitals. However, critics argue that these measures are reactive, not preventive, and call for a national overhaul of the drug certification process.

Meanwhile, the families continue their quiet battles – demanding answers, seeking compensation, and urging the system to protect the next mother who walks through a hospital door. Their voices, though bruised, have become the catalyst for change, and for many, the only way to give meaning to the lives that were so abruptly taken.

As India mourns one of the gravest maternity setbacks in recent memory, the tragedy in Kota serves as a stark warning: the health of a nation rests not only on the competence of its doctors, but equally on the integrity of the medicines they administer.